A meta-analysis on application and prospect of cell therapy in the treatment of diabetes mellitus
Abstract Objective Diabetes mellitus (DM) is a grave autoimmune disorder because of no insulin self-generation. Currently, mainly clinical methods exist, serious adverse effects leading to stem cell therapy are considered. The mesenchymal stem cells (MSCs), require high differentiation capacity and...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | Stem Cell Research & Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13287-025-04377-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849325743772794880 |
|---|---|
| author | Hanluo Li Cheng Chen Yuansheng Wang Wei Yi Peipei Guo Chenguang Yao Jinbiao Liu Yanhong Wei Kanghong Hu Xiaoke Shang Sini Kang |
| author_facet | Hanluo Li Cheng Chen Yuansheng Wang Wei Yi Peipei Guo Chenguang Yao Jinbiao Liu Yanhong Wei Kanghong Hu Xiaoke Shang Sini Kang |
| author_sort | Hanluo Li |
| collection | DOAJ |
| description | Abstract Objective Diabetes mellitus (DM) is a grave autoimmune disorder because of no insulin self-generation. Currently, mainly clinical methods exist, serious adverse effects leading to stem cell therapy are considered. The mesenchymal stem cells (MSCs), require high differentiation capacity and are judged as crucial in DM treatment. The meta-analysis aimed to systemically analyze the particular types of MSCs which play a more important role in DM and which DM is treated more effectively. Method A systematic review was conducted on the published literature, clinical trials and observational studies, utilizing databases such as PubMed, Embase, Cochrane and clinicaltrial.gov. RevMan software was adopted to draw Forest Plot and Funnel Plot, and subgroup analysis were employed to evaluate heterogeneity between different groups. Results We identified the meta-analyses of 34 unique random controlled trials and divided our own systematic reviews into 8 groups. The MSCs were associated with placebo (OR = 2.79, 95% CI [1.63, 4.75]), Standard Clinical Treatment (SCT) (OR = 4.12, 95% CI [2.76, 6.14]), and monocyte (OR = 6.52, 95% CI [3.56, 9.48]). The comparison between Autologous MSCs and Allogenic MSCs (OR = 4.64, 95% CI [3.42, 6.31]), Autologous BMMSCs and other MSCs (OR = 5.28, 95% CI [3.64, 7.66]), Allogenic ASCs and UCMSCs (OR = 3.54, 95% CI [1.83, 6.86]), Type I DM and Type II DM (OR = 3.10, 95% CI [1.79, 5.38]), intravenous injection and other injections (OR = 4.81, 95% CI [3.34, 6.94]), diabetic foot ulcers and diabetic neurological disease (OR = 3.88,,95% CI [2.53,5.95]). Conclusion Current evidence suggests that MSCs hold significant potential for treating DM, demonstrating considerably high safety and efficacy. MSCs exhibit higher therapeutic benefits compared to monocytes, with autologous MSCs offering better clinical outcomes than allogenic sources. MSCs (BMMSCs) proved more effective than other types of MSCs. However, no significant differences were observed between adipose-derived MSCs (ASCs) and umbilical cord-derived MSCs (UCMSCs) in the allogeneic setting. Moreover, MSCs show more pronounced therapeutic effects in Type II DM, and the difference among the injection methods is minimally observed. In conclusion, the research scope on DM is relatively limited in this study and further research is necessary to improve the reliability of the estimates. |
| format | Article |
| id | doaj-art-9f6a0ca8f8b24728a2eb9a16a8c6d914 |
| institution | Kabale University |
| issn | 1757-6512 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | BMC |
| record_format | Article |
| series | Stem Cell Research & Therapy |
| spelling | doaj-art-9f6a0ca8f8b24728a2eb9a16a8c6d9142025-08-20T03:48:19ZengBMCStem Cell Research & Therapy1757-65122025-05-0116112710.1186/s13287-025-04377-4A meta-analysis on application and prospect of cell therapy in the treatment of diabetes mellitusHanluo Li0Cheng Chen1Yuansheng Wang2Wei Yi3Peipei Guo4Chenguang Yao5Jinbiao Liu6Yanhong Wei7Kanghong Hu8Xiaoke Shang9Sini Kang10National “111” Center for Cellular Regulation and Molecular Pharmaceutics, Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), Hubei University of TechnologyNational “111” Center for Cellular Regulation and Molecular Pharmaceutics, Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), Hubei University of TechnologyNational “111” Center for Cellular Regulation and Molecular Pharmaceutics, Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), Hubei University of TechnologyNational “111” Center for Cellular Regulation and Molecular Pharmaceutics, Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), Hubei University of TechnologyNational “111” Center for Cellular Regulation and Molecular Pharmaceutics, Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), Hubei University of TechnologyNational “111” Center for Cellular Regulation and Molecular Pharmaceutics, Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), Hubei University of TechnologyNational “111” Center for Cellular Regulation and Molecular Pharmaceutics, Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), Hubei University of TechnologyNational “111” Center for Cellular Regulation and Molecular Pharmaceutics, Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), Hubei University of TechnologyNational “111” Center for Cellular Regulation and Molecular Pharmaceutics, Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), Hubei University of TechnologyNational “111” Center for Cellular Regulation and Molecular Pharmaceutics, Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), Hubei University of TechnologyNational “111” Center for Cellular Regulation and Molecular Pharmaceutics, Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), Hubei University of TechnologyAbstract Objective Diabetes mellitus (DM) is a grave autoimmune disorder because of no insulin self-generation. Currently, mainly clinical methods exist, serious adverse effects leading to stem cell therapy are considered. The mesenchymal stem cells (MSCs), require high differentiation capacity and are judged as crucial in DM treatment. The meta-analysis aimed to systemically analyze the particular types of MSCs which play a more important role in DM and which DM is treated more effectively. Method A systematic review was conducted on the published literature, clinical trials and observational studies, utilizing databases such as PubMed, Embase, Cochrane and clinicaltrial.gov. RevMan software was adopted to draw Forest Plot and Funnel Plot, and subgroup analysis were employed to evaluate heterogeneity between different groups. Results We identified the meta-analyses of 34 unique random controlled trials and divided our own systematic reviews into 8 groups. The MSCs were associated with placebo (OR = 2.79, 95% CI [1.63, 4.75]), Standard Clinical Treatment (SCT) (OR = 4.12, 95% CI [2.76, 6.14]), and monocyte (OR = 6.52, 95% CI [3.56, 9.48]). The comparison between Autologous MSCs and Allogenic MSCs (OR = 4.64, 95% CI [3.42, 6.31]), Autologous BMMSCs and other MSCs (OR = 5.28, 95% CI [3.64, 7.66]), Allogenic ASCs and UCMSCs (OR = 3.54, 95% CI [1.83, 6.86]), Type I DM and Type II DM (OR = 3.10, 95% CI [1.79, 5.38]), intravenous injection and other injections (OR = 4.81, 95% CI [3.34, 6.94]), diabetic foot ulcers and diabetic neurological disease (OR = 3.88,,95% CI [2.53,5.95]). Conclusion Current evidence suggests that MSCs hold significant potential for treating DM, demonstrating considerably high safety and efficacy. MSCs exhibit higher therapeutic benefits compared to monocytes, with autologous MSCs offering better clinical outcomes than allogenic sources. MSCs (BMMSCs) proved more effective than other types of MSCs. However, no significant differences were observed between adipose-derived MSCs (ASCs) and umbilical cord-derived MSCs (UCMSCs) in the allogeneic setting. Moreover, MSCs show more pronounced therapeutic effects in Type II DM, and the difference among the injection methods is minimally observed. In conclusion, the research scope on DM is relatively limited in this study and further research is necessary to improve the reliability of the estimates.https://doi.org/10.1186/s13287-025-04377-4MSCsAutologous MSCsAllogenic MSCsType I DMType II DMExosomes |
| spellingShingle | Hanluo Li Cheng Chen Yuansheng Wang Wei Yi Peipei Guo Chenguang Yao Jinbiao Liu Yanhong Wei Kanghong Hu Xiaoke Shang Sini Kang A meta-analysis on application and prospect of cell therapy in the treatment of diabetes mellitus Stem Cell Research & Therapy MSCs Autologous MSCs Allogenic MSCs Type I DM Type II DM Exosomes |
| title | A meta-analysis on application and prospect of cell therapy in the treatment of diabetes mellitus |
| title_full | A meta-analysis on application and prospect of cell therapy in the treatment of diabetes mellitus |
| title_fullStr | A meta-analysis on application and prospect of cell therapy in the treatment of diabetes mellitus |
| title_full_unstemmed | A meta-analysis on application and prospect of cell therapy in the treatment of diabetes mellitus |
| title_short | A meta-analysis on application and prospect of cell therapy in the treatment of diabetes mellitus |
| title_sort | meta analysis on application and prospect of cell therapy in the treatment of diabetes mellitus |
| topic | MSCs Autologous MSCs Allogenic MSCs Type I DM Type II DM Exosomes |
| url | https://doi.org/10.1186/s13287-025-04377-4 |
| work_keys_str_mv | AT hanluoli ametaanalysisonapplicationandprospectofcelltherapyinthetreatmentofdiabetesmellitus AT chengchen ametaanalysisonapplicationandprospectofcelltherapyinthetreatmentofdiabetesmellitus AT yuanshengwang ametaanalysisonapplicationandprospectofcelltherapyinthetreatmentofdiabetesmellitus AT weiyi ametaanalysisonapplicationandprospectofcelltherapyinthetreatmentofdiabetesmellitus AT peipeiguo ametaanalysisonapplicationandprospectofcelltherapyinthetreatmentofdiabetesmellitus AT chenguangyao ametaanalysisonapplicationandprospectofcelltherapyinthetreatmentofdiabetesmellitus AT jinbiaoliu ametaanalysisonapplicationandprospectofcelltherapyinthetreatmentofdiabetesmellitus AT yanhongwei ametaanalysisonapplicationandprospectofcelltherapyinthetreatmentofdiabetesmellitus AT kanghonghu ametaanalysisonapplicationandprospectofcelltherapyinthetreatmentofdiabetesmellitus AT xiaokeshang ametaanalysisonapplicationandprospectofcelltherapyinthetreatmentofdiabetesmellitus AT sinikang ametaanalysisonapplicationandprospectofcelltherapyinthetreatmentofdiabetesmellitus AT hanluoli metaanalysisonapplicationandprospectofcelltherapyinthetreatmentofdiabetesmellitus AT chengchen metaanalysisonapplicationandprospectofcelltherapyinthetreatmentofdiabetesmellitus AT yuanshengwang metaanalysisonapplicationandprospectofcelltherapyinthetreatmentofdiabetesmellitus AT weiyi metaanalysisonapplicationandprospectofcelltherapyinthetreatmentofdiabetesmellitus AT peipeiguo metaanalysisonapplicationandprospectofcelltherapyinthetreatmentofdiabetesmellitus AT chenguangyao metaanalysisonapplicationandprospectofcelltherapyinthetreatmentofdiabetesmellitus AT jinbiaoliu metaanalysisonapplicationandprospectofcelltherapyinthetreatmentofdiabetesmellitus AT yanhongwei metaanalysisonapplicationandprospectofcelltherapyinthetreatmentofdiabetesmellitus AT kanghonghu metaanalysisonapplicationandprospectofcelltherapyinthetreatmentofdiabetesmellitus AT xiaokeshang metaanalysisonapplicationandprospectofcelltherapyinthetreatmentofdiabetesmellitus AT sinikang metaanalysisonapplicationandprospectofcelltherapyinthetreatmentofdiabetesmellitus |